We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-15.00 | -0.91% | 1,636.00 | 1,638.00 | 1,639.00 | 1,661.50 | 1,635.50 | 1,656.50 | 4,329,161 | 16:35:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.69 | 67.46B |
Date | Subject | Author | Discuss |
---|---|---|---|
22/5/2020 11:41 | Interleukin 7 | the white house | |
22/5/2020 11:15 | One issue with all the big pharma's is that they have to run to stand still. The replacement of revenues from patent expiring drugs is just very difficult. All big pharma's will hit this at some point - it all depends upon the profile of their portfolios. | alphorn | |
22/5/2020 11:03 | Can you tell me why GSK no shareprice growth for 25 years, in fact ever since they bought SKB they never gone above 2000p in almost 35 years.Ok 4.5% yield, so to me GSK ord is just like a corporate bond but with more risk. | montyhedge | |
22/5/2020 07:43 | Gsk missed out on the vaccine, Astra Zeneca stole the show. | montyhedge | |
22/5/2020 07:21 | Being a holder of both AZN and GSK the former has been a much better investment. It is striking how much more successful drug development AZN has over GSK which is the main difference between the two. | our haven | |
21/5/2020 16:46 | Yes GSK shareprice below what they were 25 years ago no growth, but a 4.5% dividend. | montyhedge | |
21/5/2020 16:22 | AZN up 50% since March lows!Picked the wrong one to invest here | watfordhornet | |
21/5/2020 16:09 | When the pandemic started both AZN and GSK issued a statement saying that were together to produce the vaccine now no mention of GSK? | abdullla | |
21/5/2020 15:44 | jade - smile! Zantac had superior marketing. ;) In this instance we are all winners if there are plenty of 'fast followers'. | alphorn | |
21/5/2020 15:42 | or should we be more worried about stopping a pandemic? | bothdavis | |
21/5/2020 15:33 | Who won the race to produce an anti ulcer drug, SKBeecham with Cimetidine, or Glaxo with Ranitidine? Did the first one to reach the tape achieve the highest earnings??? | jadeticl3 | |
21/5/2020 14:27 | And rightly so! spud | spud | |
21/5/2020 12:58 | AZN wins the vaccine race! | abdullla | |
21/5/2020 11:51 | I don't understand the comparison between a merged entity of essentially 4 pharmas with GW pre merger? How can you compare the two? Surely the comparison against peers is better? Anyway, as someone pointed out before it's doing about the same as it was pre-pandemic so not too bad really. | rikky72 | |
21/5/2020 11:47 | So the share price has not changed for the past 25 years, to me it means the 25 years old wine in the cask is well matured may be soon we all have a drink. | abdullla | |
21/5/2020 11:05 | The only problem with GSK ord shares, it's trades like a corporate bond, ok yield 4.5%.But shareprice below what it was 25 years ago. So hope boys on here not long term investors, lol | montyhedge | |
21/5/2020 10:47 | Thanks TM this is what I was talking about,I think it is a brand new set up for innovations into vaccine related discoveries good luck to them scientists their results is the key. | abdullla | |
21/5/2020 09:39 | abdullla - if you don't like it, sell up and move on.....please!!! | robbiekeane | |
21/5/2020 09:31 | Bad news is that share price is back to square one | abdullla | |
20/5/2020 16:22 | Ladies n gents the good news is ftse 100 is on the Rise Again 😆 | riz000 | |
20/5/2020 16:10 | Just look at the price fluctuations or shall I say manipulation going on . | abdullla | |
20/5/2020 15:40 | They say invest for long term but GSK shareprice below what it was 25 years ago. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions